Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). The OPDP issued a warning letter to the drugmaker—dated May 29 and publicly released this week—to express concerns over an Instagram post from Sprout’s CEO about Addyi, the company’s prescription pill for hypoactive sexual desire disorder (HSDD) in women. The post in question is from July 1, 2024. Cindy Eckert, Sprout’s CEO and founder, shared a screenshot of a People magazine article in which a woman shared her positive experience with Addyi; the article brands Addyi as “the sex pill for women.” In her caption accompanying the post, Eckert wrote in part, “This has never been about a pill at all. This is about dismantling a double standard that shouldn’t have been there in the first place.” She added, “The first articles on [Addyi] a decade ago questioned the women struggling, told them it was normal, debated how many more satisfying sexual events were enough for them to deserve a pill…Today People Magazine let a woman speak for herself. I hope it helps countless others.” The OPDP took issue with the post being promotional in nature without also including information about Addyi’s risks, limitations and full
Read More